HELIUS MEDICAL TECHNOLOGIES, INC. Financials Helius Medical Technologies, Inc. Toronto S.E.
Equities
HSM
US42328V1089
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CAD | -.--% |
|
+4.21% | -.--% |
| Apr. 24 | Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center | CI |
| Apr. 03 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29.8 | 19.57 | 20.66 | 8.656 | 5.694 | 10.73 | - | - |
| Enterprise Value (EV) 1 | 29.8 | 19.57 | 20.66 | 8.656 | 5.694 | 10.73 | 10.73 | 10.73 |
| P/E ratio | -2.62 x | -1.12 x | -0.7 x | -0.3 x | -0.55 x | -0.38 x | -0.9 x | 1.74 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 19.9 x | 29.6 x | 39.6 x | 11 x | 8.84 x | 11 x | 1.88 x | 0.53 x |
| EV / Revenue | 19.9 x | 29.6 x | 39.6 x | 11 x | 8.84 x | 11 x | 1.88 x | 0.53 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17.6 | 29.7 | 79.6 | 564 | 708 | 2,690 | - | - |
| Reference price 2 | 1,698 | 659.1 | 259.5 | 15.34 | 8.039 | 3.990 | 3.990 | 3.990 |
| Announcement Date | 3/12/20 | 3/10/21 | 3/14/22 | 3/9/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.496 | 0.661 | 0.522 | 0.787 | 0.644 | 0.977 | 5.717 | 20.33 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -24 | -14.39 | -18.14 | -15.52 | -12.43 | -11.61 | -12.69 | 5.602 |
| Operating Margin | -1,604.01% | -2,176.4% | -3,475.48% | -1,971.54% | -1,929.81% | -1,188.81% | -222.05% | 27.56% |
| Earnings before Tax (EBT) 1 | -9.781 | -14.13 | - | -14.07 | -8.85 | -8.728 | -7.21 | 5.602 |
| Net income 1 | -9.781 | -14.13 | -18.16 | -14.07 | -8.85 | -11.61 | -9.357 | 5.602 |
| Net margin | -653.81% | -2,137.67% | -3,478.54% | -1,788.06% | -1,374.22% | -1,188.81% | -163.66% | 27.56% |
| EPS 2 | -647.5 | -590.0 | -369.0 | -52.00 | -14.56 | -10.50 | -4.420 | 2.290 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/10/21 | 3/14/22 | 3/9/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.109 | 0.258 | 0.19 | 0.119 | 0.196 | 0.282 | 0.111 | 0.256 | 0.143 | 0.134 | 0.1305 | 0.158 | 0.2005 | 0.488 | 1.49 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.373 | -4.102 | -4.564 | -3.43 | -4.853 | -2.669 | -3.81 | -3.219 | -3.153 | -2.246 | -2.935 | -2.577 | -2.75 | -2.71 | -3.32 |
| Operating Margin | -4,011.93% | -1,589.92% | -2,402.11% | -2,882.35% | -2,476.02% | -946.45% | -3,432.43% | -1,257.42% | -2,204.9% | -1,676.12% | -2,249.04% | -1,631.01% | -1,371.82% | -555.23% | -222.82% |
| Earnings before Tax (EBT) 1 | -4.687 | - | - | -3.81 | -1.03 | -4.886 | -2.494 | -1.648 | -3.663 | -1.045 | -2.298 | -2.172 | -2.175 | -2.083 | -3.32 |
| Net income 1 | -4.687 | -4.102 | -4.346 | -3.81 | -1.03 | -4.886 | -2.494 | -1.648 | -3.663 | -1.045 | -2.935 | -2.577 | -2.75 | -2.71 | -3.32 |
| Net margin | -4,300% | -1,589.92% | -2,287.37% | -3,201.68% | -525.51% | -1,732.62% | -2,246.85% | -643.75% | -2,561.54% | -779.85% | -2,249.04% | -1,631.01% | -1,371.82% | -555.23% | -222.82% |
| EPS 2 | -100.5 | -65.50 | -57.50 | -48.50 | -6.000 | -8.500 | -4.500 | -3.000 | -5.490 | -0.9600 | -3.870 | -2.255 | -2.390 | -2.045 | -0.6600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/14/22 | 5/12/22 | 8/15/22 | 11/14/22 | 3/9/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 0.06 | 0.05 | 0.02 | 0.03 | - | - | - |
| Capex / Sales | - | 9.53% | 10.34% | 2.16% | 4.5% | - | - | - |
| Announcement Date | 3/12/20 | 3/10/21 | 3/14/22 | 3/9/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.99
USD
Average target price
15.47
USD
Spread / Average Target
+287.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.15% | 217B | |
| +6.60% | 183B | |
| +9.86% | 131B | |
| +24.32% | 106B | |
| -0.95% | 62.16B | |
| +11.04% | 51.02B | |
| +4.81% | 50.89B | |
| -1.43% | 40.16B | |
| +24.40% | 31.44B |
- Stock Market
- Equities
- HSDT Stock
- HSM Stock
- Financials Helius Medical Technologies, Inc.
